• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Digital health start-up Amalgam Rx launches with insulin titration app

May 1, 2017 By Sarah Faulkner

Amalgam RxDigital health start-up Amalgam Rx launched today with the release of iSage Rx, which it touts as the 1st FDA 510(k)-cleared, prescription mobile app for insulin titration.

The app allows physicians to choose from clinically-validated basal insulin algorithms and tailor them to the needs of their patients with Type II diabetes. Patients record their blood glucose levels and if their levels are not under control, the app can suggest an increase in insulin based on their doctor’s recommendation.

Although Amalgam is focused on helping patients manage Type II diabetes, the company hopes to partner with pharmaceutical companies and develop other medication-app combinations, according to Business Insider. 

“Initiating and intensifying insulin are 2 of the more daunting challenges in managing patients with Type II diabetes. This is particularly true in primary care where insulin initiation is often delayed up to 6 years. And, when patients do start insulin, they tend to stay on a sub-optimal dose for too long,” Dr. Philip Levin, endocrinologist at Baywest Endocrinology Center, said in prepared remarks. “Tools like the iSage app are critical to supporting patient self-management and helping them overcome many of the barriers to starting and optimizing insulin management such as myth-based fears and social stigma of using insulin, low literacy and numeracy levels, and other real and perceived barriers.”

iSage Rx is conducting a clinical trial and said it expects to be finished by the end of this year.

“We’re not focused on becoming the operating system for patients with Type II diabetes; there are a lot of companies working on that. Instead, we’re committed to creating the best insulin titration engine for patients with Type II diabetes. Today’s launch of iSage Rx is the first step but, at this point, we’re really just scratching the surface,” founder & CEO Ryan Sysko said. “While we have developed an application or interface to test the efficacy of iSage, our ultimate goal is to provide insulin titration as a service. We want to enable the companies that are creating the operating systems for diabetes to easily integrate insulin titration. As we move forward, we’re working on leveraging data science, integrating BGM and CGM glucose sensors, and connecting with dose capture devices to create highly personalized and precise algorithms.”

Filed Under: Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Pharmaceuticals Tagged With: amalgamrx

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS